

Referensi

- Aaronsen NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, et al. Compromised Health-Related Quality of Life in Patients with Low-Grade Glioma. *J Clin Oncol*. 2011; 29:4430–4435. [PubMed: 22010018]
- Adamson Cory KOO, Mehta Ankit I, Di Chunhui, Lin Ningjing, Mattox Austin K, Bigner Darell D. Glioblastoma multiforme: a review of where we have been and where we are going. *Expert Opin Investig Drugs* 2009;18:1061-83
- Aldape K, Xadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. *Acta Neuropathol* 2015;129(6):829-48.
- Altieri R, Agnoletti A, Quattrucci F, Garbossa D, Calamo F, Bozzaro M, et al. Molecular biology of gliomas: present and future challenges. *Translational Medicine*. 2014;10(7):29-37.
- Amidei C, Kushner D. Clinical implications of motor deficits related to brain tumors. *Neuro-Oncology Practice*. 2015;2(4):179-84.
- Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolamide chemotherapy in patients with WHO grade II gliomas. *Ann Oncol*. 2003; 14:1715–1721. [PubMed: 14630674]
- Bruckner J. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. *J Clin Oncol*. 2014; 32:5s.
- Chaichana K, Martinez-Gutierrez JC, Ramos R, WEingart J, Olivi A, et al. Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. *J Clin Neurosci*. 2013;20(6):818-23.
- Claus E, Walsh K, Wiencke J, Molinaro A, Wiemels J, et al. Survival and low grade glioma: the emergence of genetic information. *Neurosurg Focus*. 2015 January ; 38(1): E6.
- Cohen A, Holmen S, Colman H. IDH1 and IDH2 Mutations in Gliomas. *Curr Neurol Neurosci Rep*. 2013;13(5):345.
- Combs S, Rieken S, Wick W, Abdollahi A, Deimling A, Debus J, et al. Prognostic Significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? *Radiation Oncology*. 2011; 6:115
- Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. *J Neurooncol*. 2008; 86:321–327. [PubMed: 17926007]

- Darlix Amélie, Catherine Gozé, Valérie Rigau, Luc Bauchet, Luc Taillandier, Hugues Duffau. The etiopathogenesis of diffuse low-grade gliomas. *Critical Reviews in Oncology/Hematology* 109 (2017) 51–62.
- Duffau H, Capelle L. Preferential Brain Locations of Low-Grade Gliomas. 2004. *American Cancer Society*:2622-26.
- El-Zein R, Bondy M, Wrensch M. Epidemiology of Brain Tumors. In: Francis Ali-Osman. *Contemporary Cancer Research. Brain Tumors*. Humana Press. New Jersey. 2005.
- Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. *Ann Neurol* 60:740–743.
- Ferreira W, Junior C, Rodrigues-Antunes S, Araujo M, Barros M. An update on the epigenetics of glioblastomas. *Epigenomics*. 2016. ISSN 1750-1911.
- Gladson C, Prayson R, Liu W. The Pathobiology of Glioma Tumors.. *Annu Rev Pathol*. 2010;5:33-50
- Goodenberger ML, Jenkins RB. Genetics of adult glioma. *Cancer Genetics*. 2012. 205 (12):613-21.
- Gorlia T, Stupp R, Brandes A, Rampling R, Fumoleau P, Ditttrich C, et al. New Prognostic Factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC N\Brain Tumour Group phase I and II clinical trials. *European Journal of cancer*. 2012. 48:1176-84.
- Hofer Silvia & Andrew B. Lassman. Molecular markers in gliomas: impact for the clinician. *Targ Oncol* (2010) 5:201–210 DOI 10.1007/s11523-010-0157-2.
- Hofer S, Rushing E, Preusser M, Marossi C. Molecular Biology of High-Grade Gliomas: what should the clinician know? *Chin J Cancer*. 2014;33(1):4-7.
- Huang L, Jiang T, Yuan F, Li G, Wang Z. Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. *Clinical Neurology and Neurosurgery* 110 (2008):1020-24.
- Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. *Int J Radiat Oncol Biol Phys*. 1996; 36:549–556. [PubMed: 8948338]
- Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. *Cancer* 1948;1:634-56.

- Kerkhof M, Vecht C. Seizure characteristics and prognostic factors of gliomas. *Epilepsia*. 2013;54:12-7.
- Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. *Clin Cancer Res*. 2009; 15:330–337. [PubMed: 19118062]
- Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). *Eur J Cancer*. 1998; 34:1902–1909. [PubMed: 10023313]
- Komite penanggulangan kanker Nasional. Pedoman Nasional Pelayanan Kedokteran Tumor Otak. 2017
- Larjavaara S, Mantyla R, Salminen T, Haapasalo H, Raitnen J, et al. Incidence of Gliomas by anatomic location. *Society for Neuro-Oncology*. 2007.319-25
- Lee J, Park SH, Kim YZ. Prognostic Evaluation of Neurological Assessment of the Neuro-Oncology Scale in GFlioblastoma Patients. *Brain Tumor Res Treat*. 2018;6(1):22-30.
- Liu Aizhen, Chunfeng Hou, Hongfang Chen, Xuan Zong, Peijun Zong. Genetics and epigenetics of Glioblastoma: Applications and Overall incidence of iDH1 Mutation. *Frontiers in Oncology*. Review. January 2016 doi: 10.3389/fonc.2016.00016
- Lieberman F. Glioblastoma update:molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. *F1000Research*. 2017. Doi:10.12688/f1000research.11493.1
- Liffers K, Kamszus K, Schulte A. EGFR Amplification and Glioblastoma Stem-Like Cells. *Stem Cell International*. 2015;1-11
- Louis D, Perry A, Reifenberger G, Deimling A, Figarella D, Cavenee W, Ohgaki H, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*. 2016. DOI 10.1007/s00401-016-1545-1
- Mainio A, Tuunanen S, Hakko H, Niemela A, Koivukangas J, Rasanen P. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. *Eur Arch Psychiatr Clin Neurosci*. 2006; 256:516–521.
- Mansouri A. Karamchandani J. Das S. Molecular Genetics of Secondary Glioblastoma. Dalam: Vleschouwer S. Glioblastoma. Australia. 2017, Codon Publication.

- Marina O, Suh J, Reddy C, Barnett G, Vogelbaum M, et al. Treatment Outcomes for Patients with Glioblastoma Multiforme and a low Karnofsky Performance Scale score on Presentation to a tertiary care institution. *J Neurosurg* 2011; 115:220-9.
- Marumoto T, Saya Hideyuki. *Molecular Biology of Glioma. In: Glioma:immunotherapeutic Approaches.* 2012. Landes Bioscience and Springer Science.
- Mellai M, Caldera V, Annovazzi L, Schiffer D. The Distribution and Significance of IDH Mutations in Gliomas. *Intech. Open Science.* 2013. <http://dx.doi.org/10.5772/52357>
- Melguizo C, Prados J, Gonzalez B, Ortiz R, Concha A, Alvarez P, et al. MGMT Promoter Methylation status and MGMT and CD 133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolamide plus radiotherapy. *Journal of Translational Medicine.* 2012; 10:250
- Mueller W, et al. Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets. *Am J of Pathology.*2002;313
- Nayak L, DeAngelis L, Brandes A, Peereboom D, Galanis E, Lin N, Soffietti R, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. *Neuro-Oncology.*2017;19(5):625-35.
- Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. *Clinical Cancer Research.* 2004; 10:2618–2625. [PubMed: 15102663]
- Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* 1982;5:649-55.
- Oslobanu A, Florian St.I. Anatomic locations in high grade glioma. *Romanian Neurosurgery (2015) XXIX 3:271-7.*
- Ostrom Q, Gittleman H, Fulop J, Liu M, Blanda R, Kramer C, Wolinsky Y, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2008-2012. *Neuro-Oncology,* 2015. Doi:10.1093/neuonc/nov189.
- Padfield E, Ellis H, Kurian K. Current therapeutics advances targeting EGFR and EGFRvIII in glioblastoma. *Frontiers in Oncology.* 2015 (5)5:1-8.
- Parsons DW JS, Zhang X. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807-12

- Rivera A, Pelloski C, Gilbert M, Colman H, Cruz C, Sulman E, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. *Neuro-Oncology*. 2010; 12(2):116-21.
- Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. *J Clin Oncol*. 2002; 120:2267–2276. [PubMed: 11980997]
- Stege EM, Kros JM, de Brulin HG, Enting RH, van Heuvel I, Looijenga LH, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. *Cancer*. 2005; 103:802–809. [PubMed: 15637687]
- Qi SongTao, Yu Lei, Gui Si, Ding YanQing, Han HuiXia, Zhang XueLin, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. *Cancer Science*. 2011;103:269-273.
- Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolamide in patients with progressive low-grade glioma. *J Clin Oncol*. 2003; 21:646–651. [PubMed: 12586801]
- Sajad Hussain Arif AAP, Abdul Rashid Bhat, Altaf Umar Ramzan, Nayil Khursheed Malik, Sarabjit S. Chibber, Abrar A. Wani, Rehana, Kirmani TaA. EGFR and PTEN Gene Mutation Status in Glioblastoma Patients and their Prognostic Impact on Patient's Survival. *J Carcinog Mutagen* 2015;6
- Schag CC, Heinrich RL, Ganz PA. Karnofsky Performance Status revisited: Reliability, validity, and guidelines. *J Clin Oncology*. 1984;2:187-93.
- Senhaji N, Louati S, Chbani L, Fatemi H, Hammas N, Mikou K, et al. EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco. 2017; 1-7
- Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, et al. Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme. *CANCER RESEARCH* 63, 6962–6970, October 15, 2003
- Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. *Int J Radiat Oncol Biol Phys*. 1993;26:239-44.

- Taylor T, Furnari F, Cavanee W. Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. *Curr Cancer Drug Targets*. 2012;12(3):197-209.
- Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. *J Neurooncol*. 2008; 89:179–185. [PubMed: 18431544]
- Van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. *J Clin Oncol* 27:5881–5886
- Van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. *Lancet*. 2005; 366:985–990. [PubMed: 16168780]
- Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, et al. Analysis of EGFR Overexpression, *EGFR* Gene Amplification and the EGFRvIII Mutation in Portuguese High-grade Gliomas. *ANTICANCER RESEARCH*. 2008; 28: 913-920 2008.
- Walid MS. Prognostic Factors for Long-Term Survival after Glioblastoma. *The Permanente Journal* 2008;12.
- Yan H PD, McLendon R. IDH1 and IDH2 mutations in gliomas. *N Eng J Med* 2009;360:765-73.
- Zhang J, Chen Y, Li Y, et al. Postoperative functional status in patients with supratentorial superficial low-grade glioma. *World J of Surgical Oncology*. 2017;15:186.
- Zhang Xiang ZW, Cao wei Dong, Cheng Gang, Zhang Yong Qiang. Glioblastoma multiforme: molecular characterization and current treatment strategy. *Experimental and Therapeutic Medicine* 2012;3:9-14

Lampiran

Lembar Penilaian Skala NANO

Scoring assessment is based on direct observation and testing performed during clinical evaluation and is not based on historical information or reported symptoms. Please check 1 answer per domain. Please check "Not assessed" if testing for that domain is not done. Please check "Not evaluable" if a given domain cannot be scored accurately due to pre-existing conditions, co-morbid events and/or concurrent medications.

Patient Identifier: _____

Date Assessment Performed (day/month/year): _____

Study time point (i.e. baseline, cycle 1, day 1, etc): _____

Assessment performed by (please print name): _____

Domains

Gait

- 0 Normal
1 Abnormal but walks without assistance
2 Abnormal and requires assistance
(companion, cane, walker, etc.)
3 Unable to walk
 Not assessed
 Not evaluable

Strength

- 0 Normal
1 Movement present but decreased
against resistance
2 Movement present but none against resistance
3 No movement
 Not assessed
 Not evaluable

Ataxia (upper extremity)

- 0 Able to finger to nose touch without difficulty
1 Able to finger to nose touch but difficult
2 Unable to finger to nose touch
 Not assessed
 Not evaluable

Sensation

- 0 Normal
1 Decreased but aware of sensory modality
2 Unaware of sensory modality
 Not assessed
 Not evaluable

Key Considerations

- Walking is ideally assessed by at least 10 steps

- Test each limb separately
- Recommend assess proximal (above knee or elbow) and distal (below knee or elbow) major muscle groups
- Score should reflect worst performing area
- Patients with baseline level 3 function in one major muscle group/limb can be scored based on assessment of other major muscle groups/limb

- Non-evaluable if strength is compromised
- Trunk/lower extremities assessed by gait domain
- Particularly important for patients with brainstem and cerebellar tumors
- Score based on best response of at least 3 attempts

- Recommend evaluating major body areas separately (face, limbs and trunk)
- Score should reflect worst performing area
- Sensory modality includes but not limited to light touch, pinprick, temperature and proprioception
- Patients with baseline level 2 function in one major body area can be scored based on assessment of other major body areas

Scoring assessment is based on direct observation and testing performed during clinical evaluation and is not based on historical information or reported symptoms. Please check 1 answer per domain. Please check "Not assessed" if testing for that domain is not done. Please check "Not evaluable" if a given domain cannot be scored accurately due to pre-existing conditions, co-morbid events and/or concurrent medications.

Visual Fields

- 0 Normal
- 1 Inconsistent or equivocal partial hemianopsia (≥quadrantanopsia)
- 2 Consistent or unequivocal partial hemianopsia (≥quadrantanopsia)
- 3 Complete hemianopsia
- Not assessed
- Not evaluable

- Patients who require corrective lenses should be evaluated while wearing corrective lenses
- Each eye should be evaluated and score should reflect the worst performing eye

Facial Strength

- 0 Normal
- 1 Mild/moderate weakness
- 2 Severe facial weakness
- Not assessed
- Not evaluable

- Particularly important for brainstem tumors
- Weakness includes nasolabial fold flattening, asymmetric smile and difficulty elevating eyebrows

Language

- 0 Normal
- 1 Abnormal but easily conveys meaning to examiner
- 2 Abnormal and difficulty conveying meaning to examiner
- 3 Abnormal. If verbal, unable to convey meaning to examiner. OR non-verbal (mute/global aphasia)
- Not assessed
- Not evaluable

- Assess based on spoken speech. Non-verbal cues or writing should not be included.
- **Level 1:** Includes word finding difficulty; few paraphasic errors/neologisms/word substitutions; but able to form sentences (full/broken)
- **Level 2:** Includes inability to form sentences (<4 words per phrase/sentence); limited word output; fluent but "empty" speech.

Level of Consciousness

- 0 Normal
- 1 Drowsy (easily arousable)
- 2 Somnolent (difficult to arouse)
- 3 Unarousable/coma
- Not assessed
- Not evaluable

- None

Behavior

- 0 Normal
- 1 Mild/moderate alteration
- 2 Severe alteration
- Not assessed
- Not evaluable

- Particularly important for frontal lobe tumors
- Alteration includes but is not limited to apathy, disinhibition and confusion
- Consider subclinical seizures for significant alteration

Tanggal	Skor NANO awal	Tanggal	Skor NANO 2 bln post op	Selisih NANO (Awal – 2 bln)